reduced-dose gadolinium-based contrast agent

This refers to a clinical protocol being evaluated in a Phase 1 trial at the University of Alabama at Birmingham (UAB) involving the administration of a 75% reduced dose (0.025 mmol/kg) of gadolinium-based contrast agents (GBCAs) for breast MRI. The protocol utilizes artificial intelligence (AI) software, specifically SubtleGAD (developed by Subtle Medical and distributed by GE Healthcare), to enhance low-dose images to match the diagnostic quality of standard-dose (0.1 mmol/kg) scans. The primary objective is to maintain high sensitivity and specificity for characterizing benign and malignant breast tumors while minimizing patient exposure to gadolinium and reducing potential deposition in the brain and other tissues. The study is supported by Bracco Diagnostics Inc.

Other names

low-dose gadolinium0.025 mmol/kg gadolinium